FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361945255> ?p ?o ?g. }

• W4361945255 abstract "<div>Abstract<p><b>Purpose:</b> Visfatin is an adipocytokine involved in cellular metabolism, inflammation, and cancer. This study investigated the roles of extracellular visfatin in breast cancer, and explored underlying mechanisms in clinical and experimental settings.</p><p><b>Experimental Design:</b> Associations of serum visfatin with clinicopathologic characteristics and patient survival were assessed with Cox regression models and Kaplan–Meier analyses. Effects of extracellular visfatin on cultured breast cancer cells were examined, followed by <i>in vivo</i> investigation of tumor growth and metastasis in xenograft animal models. Imatinib and Stattic were used to inhibit c-Abl and STAT3 activation, respectively.</p><p><b>Results:</b> Breast cancer patients with high serum visfatin levels were associated with advanced tumor stage, increased tumor size and lymph node metastasis, and poor survival. Elevated phosphorylation of c-Abl and STAT3 in breast tumor tissues were correlated with high serum visfatin levels in patients. Visfatin-promoted <i>in vitro</i> cell viability and metastatic capability were suppressed by imatinib (c-Abl inhibitor) and Stattic (STAT3 inhibitor). Increased <i>in vivo</i> cell invasiveness was observed in zebrafish xenografted with visfatin-pretreated breast cancer cells. Tumor growth and lung metastasis occurred in visfatin-administered mice xenografted with breast cancer cells. Tail vein–injected mice with visfatin-pretreated breast cancer cells showed increased lung metastasis, which was suppressed by imatinib.</p><p><b>Conclusions:</b> Serum visfatin levels in breast cancer patients reveal potential prognostic values, and our findings that visfatin promoted breast cancer through activation of c-Abl and STAT3 may provide an important molecular basis for future design of targeted therapies that take into account different serum visfatin levels in breast cancer. <i>Clin Cancer Res; 22(17); 4478–90. ©2016 AACR</i>.</p></div>" @default.
• W4361945255 created "2023-04-05" @default.
• W4361945255 creator A5004695493 @default.
• W4361945255 creator A5006129657 @default.
• W4361945255 creator A5010892850 @default.
• W4361945255 creator A5011670949 @default.
• W4361945255 creator A5025261646 @default.
• W4361945255 creator A5028006170 @default.
• W4361945255 creator A5047216868 @default.
• W4361945255 creator A5052667418 @default.
• W4361945255 creator A5061832076 @default.
• W4361945255 creator A5063595693 @default.
• W4361945255 creator A5071173421 @default.
• W4361945255 creator A5071854156 @default.
• W4361945255 creator A5074664727 @default.
• W4361945255 creator A5083509009 @default.
• W4361945255 creator A5087589105 @default.
• W4361945255 creator A5091688671 @default.
• W4361945255 date "2023-03-31" @default.
• W4361945255 modified "2023-09-26" @default.
• W4361945255 title "Data from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation" @default.
• W4361945255 doi "https://doi.org/10.1158/1078-0432.c.6523944" @default.
• W4361945255 hasPublicationYear "2023" @default.
• W4361945255 type Work @default.
• W4361945255 citedByCount "0" @default.
• W4361945255 crossrefType "posted-content" @default.
• W4361945255 hasAuthorship W4361945255A5004695493 @default.
• W4361945255 hasAuthorship W4361945255A5006129657 @default.
• W4361945255 hasAuthorship W4361945255A5010892850 @default.
• W4361945255 hasAuthorship W4361945255A5011670949 @default.
• W4361945255 hasAuthorship W4361945255A5025261646 @default.
• W4361945255 hasAuthorship W4361945255A5028006170 @default.
• W4361945255 hasAuthorship W4361945255A5047216868 @default.
• W4361945255 hasAuthorship W4361945255A5052667418 @default.
• W4361945255 hasAuthorship W4361945255A5061832076 @default.
• W4361945255 hasAuthorship W4361945255A5063595693 @default.
• W4361945255 hasAuthorship W4361945255A5071173421 @default.
• W4361945255 hasAuthorship W4361945255A5071854156 @default.
• W4361945255 hasAuthorship W4361945255A5074664727 @default.
• W4361945255 hasAuthorship W4361945255A5083509009 @default.
• W4361945255 hasAuthorship W4361945255A5087589105 @default.
• W4361945255 hasAuthorship W4361945255A5091688671 @default.
• W4361945255 hasConcept C121608353 @default.
• W4361945255 hasConcept C126322002 @default.
• W4361945255 hasConcept C2779013556 @default.
• W4361945255 hasConcept C502942594 @default.
• W4361945255 hasConcept C530470458 @default.
• W4361945255 hasConcept C71924100 @default.
• W4361945255 hasConceptScore W4361945255C121608353 @default.
• W4361945255 hasConceptScore W4361945255C126322002 @default.
• W4361945255 hasConceptScore W4361945255C2779013556 @default.
• W4361945255 hasConceptScore W4361945255C502942594 @default.
• W4361945255 hasConceptScore W4361945255C530470458 @default.
• W4361945255 hasConceptScore W4361945255C71924100 @default.
• W4361945255 hasLocation W43619452551 @default.
• W4361945255 hasOpenAccess W4361945255 @default.
• W4361945255 hasPrimaryLocation W43619452551 @default.
• W4361945255 hasRelatedWork W1499339123 @default.
• W4361945255 hasRelatedWork W2024594909 @default.
• W4361945255 hasRelatedWork W2789798659 @default.
• W4361945255 hasRelatedWork W2795642192 @default.
• W4361945255 hasRelatedWork W2904294837 @default.
• W4361945255 hasRelatedWork W3033874287 @default.
• W4361945255 hasRelatedWork W3088410393 @default.
• W4361945255 hasRelatedWork W3160695097 @default.
• W4361945255 hasRelatedWork W3173207637 @default.
• W4361945255 hasRelatedWork W3183783449 @default.
• W4361945255 isParatext "false" @default.
• W4361945255 isRetracted "false" @default.
• W4361945255 workType "article" @default.